| Date Filed | Type | Description |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/22/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
4
| Shukla Sath (CEO and President) has filed a Form 4 on Spero Therapeutics, Inc.|
Txns:
| Granted 266,000 shares
@ $0 |
|
| 07/31/2023 |
8-K
| Quarterly results |
| 07/24/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 0% stake in Spero Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Aquilo Capital Management, LLC reports a 0% stake in SPERO THERAPEUTICS, INC. |
| 02/06/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Keutzer Timothy (COO) has filed a Form 4 on Spero Therapeutics, Inc.|
Txns:
| Granted 265,957 shares
@ $0
Sold 3,394 shares
@ $1.86, valued at
$6.3k
|
|
| 02/03/2023 |
4
| JOSEPH TAMARA L (Chief Legal Officer) has filed a Form 4 on Spero Therapeutics, Inc.|
Txns:
| Granted 265,957 shares
@ $0
Sold 3,394 shares
@ $1.86, valued at
$6.3k
|
|
| 02/03/2023 |
4
| Shukla Sath (CFO) has filed a Form 4 on Spero Therapeutics, Inc.|
Txns:
| Granted 265,957 shares
@ $0
Sold 9,504 shares
@ $1.8279, valued at
$17.4k
|
|
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/01/2023 |
8-K
| Quarterly results |
| 01/20/2023 |
SC 13D/A
| GSK PLC reports a 17.8% stake in SPERO THERAPEUTICS, INC. |
| 01/09/2023 |
8-K
| Investor presentation |
| 01/05/2023 |
4
| Tregoning Kathleen (Director) has filed a Form 4 on Spero Therapeutics, Inc.|
Txns:
| Granted 30,943 options to buy
@ $1.74, valued at
$53.8k
|
|
| 01/05/2023 |
4
| VINK PATRICK V.J.J. (Director) has filed a Form 4 on Spero Therapeutics, Inc.|
Txns:
| Granted 15,471 options to buy
@ $1.74, valued at
$26.9k
|
|
| 11/14/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 11/14/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 11/14/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
|